Cathy Eng, VICC Associate Director of Strategic Relations and Research Partnerships at Vanderbilt-Ingram Cancer, shared on X:
“Phase I/II expanded cohort study of liposomal CHK-1 inhibitor:
- 14 slots are available for patients with platinum resistant ovarian cancer (PROC)
- 17 slots are available for patients with ANCSM (no limitation on number of prior lines).
Link: Study Details | NCT06526819 | SMP-3124LP in Adults With Advanced Solid Tumors
Please contact if you have any questions.”
Other articles featuring Dr. Cathy on OncoDaily.